{"nctId":"NCT01511939","briefTitle":"Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants","startDateStruct":{"date":"2012-02"},"conditions":["Osteoarthritis of the Knee","Coagulopathy"],"count":22,"armGroups":[{"label":"Pennsaid, warfarin","type":"OTHER","interventionNames":["Drug: Pennsaid"]},{"label":"Pennsaid, dabigatran","type":"OTHER","interventionNames":["Drug: Pennsaid"]},{"label":"Pennsaid, aspirin and/or clopidogrel","type":"OTHER","interventionNames":["Drug: Pennsaid"]}],"interventions":[{"name":"Pennsaid","otherNames":["Pennsaid 1.5%","Diclofenac sodium 1.5% topical solution","Topical nonsteroidal antiinflammatory drug","Topical NSAID"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adults \\> than or equal to 55\n* Ambulatory subjects with moderate to severe osteoarthritis (OA) of the knee with symptoms and knee pain for at least 3 months and pain on the majority of days in the last 30 days.\n* Subjects with bilateral knee OA, the more symptomatic knee is the index knee and PENNSAID can be applied on both knees if both are affected.\n* Radiographic evidence of Kellgren-Lawrence Grade 2-4 within the past 2 years.\n* Currently on a stable dose of anticoagulant therapy (warfarin, dabigatran, aspirin or clopidogrel) for the past 2 months and expected to remain on current dose for the six week duration of the study.\n* If currently taking oral nonsteroidal antiinflammatory drug (NSAID) and/or acetaminophen for OA knee pain, must be taking it for at least an average of 25 days per month.\n* Those currently taking oral NSAID must be willing to perform a 7 day washout to be eligible to be enrolled into the study.\n* A pain score of \\> than 40mm on the Patient Pain Visual Analog Scale (VAS) (100 mm scale) at screening and baseline visit.\n* Able to comply with the study and give informed consent prior to performance of any study procedures.\n* Able to read, write and understand English.\n\nExclusion Criteria:\n\n* Unwilling to abstain from oral NSAIDs and/or other analgesic medication except for acetaminophen as rescue medication. Subjects taking low dose aspirin for cardiovascular health may remain on their stable dose throughout the study.\n* Unwilling to abstain from taking \\< than or equal to 1500mg of acetaminophen a day for rescue medication purposes during the 6 week course of the trial.\n* Using a handicap assistance device i.e. cane, walker \\> than or equal to 50% of the time.\n* Undergoing new physical therapy or participating in a weight loss or exercise program that has not been stable for at least 3 months prior to screening and won't remain stable during participation in study.\n* History or diagnosis of an inflammatory arthritis i.e. rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease, sarcoidosis, or amyloidosis.\n* Known or clinically suspected infection and human immunodeficiency virus (HIV), or hepatitis C or B viruses.\n* History of abnormal laboratory results \\> that or equal to 2.5 x upper limit of normal (ULN) indicative of any significant medical disease which in the opinion of the investigator, would preclude the subjects participation in the study.\n* Any of the following abnormal laboratory results during screening:\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> than or equal to 2.5 x ULN\n* Hemoglobin \\< than 11.5 g/dL (female) or \\< 13.2 g/dL (male)\n* White blood cell count (WBC) \\< than 3500 cells/mm3\n* Lymphocyte count \\< than or equal to 1000 cels/mm3\n* Serum creatinine \\> than or equal 1.5 x ULN\n* Platelet count below the central laboratory lower limit of normal (LLN)\n* Coagulation tests (Prothrombin Time (PT), Partial Thromboplastin Time (PTT), International Normalized Ratio (INR), Platelet Aggregation) requiring an alteration in anticoagulant dosage.\n* Skin breakdown or rash at knee where topical PENNSAID is to be applied.\n* Other serious uncontrolled non-malignant, significant, acute or chronic medical or psychiatric illness that, in judgment of investigator, could compromise subject safety, limit subject's ability to complete study and/or compromise the objectives of study.\n* History of malignancy in the past 5 years with exception of resected basal cell carcinoma, squamous cell carcinoma of the skin, or resected cervical atypia or carcinoma in situ.\n* History of drug or alcohol dependence or abuse in the past 3 years.","healthyVolunteers":false,"sex":"ALL","minimumAge":"55 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline to Week 4 in Laboratory Results of Prothrombin Time (PT)","description":"PT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.97","spread":null},{"groupId":"OG001","value":"0.96","spread":null},{"groupId":"OG002","value":"-0.04","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 4 in Laboratory Results of International Normalized Ratio (INR)","description":"INR will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":null},{"groupId":"OG001","value":"0.09","spread":null},{"groupId":"OG002","value":"0.00","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 4 in Laboratory Results of Partial Thromboplastin Time (PTT)","description":"PTT will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.68","spread":null},{"groupId":"OG001","value":"1.50","spread":null},{"groupId":"OG002","value":"-0.29","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline to Week 4 in Laboratory Results of Platelet Aggregation","description":"Platelet Aggregation will be evaluated to determine if there is any significant effect of Pennsaid on coagulation parameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":null},{"groupId":"OG001","value":"-39.25","spread":null},{"groupId":"OG002","value":"-13.30","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":9},"commonTop":["Swelling of lower extremities","Nausea","Influenza","Bowel Impaction","Epistaxis"]}}}